Recombinant human erythropoietin - 3SBio/Biolotus

Alternative Names: EPIAO; rESP; rhEPO; SEPO

Latest Information Update: 04 May 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 3SBio; Biolotus
Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

04 May 2022 Launched for Anaemia in China (IV) (3SBio pipeline, May 2022)
15 May 2019 Phase-II clinical trials in Anaemia in China (IV) (NCT03950687)
08 Jul 2015 Launched for Chemotherapy-induced anaemia in Brazil (IV) (SC) (Biolotus website, June 2015)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com